PI Industries has reported its audited financial results for the quarter and financial year ended March 31, 2026. The Board of Directors has recommended a final dividend of Rs. 10 per share, bringing the total dividend for the year to Rs. 15 per share. Additionally, the company announced several leadership updates, including the appointment of Dr. Atul Kumar Gupta as a Whole-time Director and the redesignation of Mr. Rajnish Sarna as a Non-Executive Director.
Financial Highlights
For the financial year ended March 31, 2026, PI Industries reported standalone revenue from operations of Rs. 61,827 million, with a profit after tax of Rs. 14,348 million. On a consolidated basis, the company achieved total income of Rs. 70,244 million for the year, resulting in a consolidated profit of Rs. 13,208 million. The company maintains a strong focus on its core Agro Chemicals segment, which remains the primary driver of revenue, alongside its growing Pharma business.
Dividend Payout
Reflecting the company’s robust financial performance, the Board of Directors has recommended a final dividend of Rs. 10 per equity share (1000% of face value) for the financial year 2025-26. Together with the interim dividend of Rs. 5 per share already paid, the total dividend payout for the year amounts to Rs. 15 per equity share. The final dividend is subject to approval by shareholders at the upcoming Annual General Meeting.
Strategic Leadership Transitions
The company announced significant changes to its leadership team to support its long-term strategic agenda:
- Dr. Atul Kumar Gupta has been appointed as an Additional Director and Whole-time Director for a term of three years, effective May 19, 2026.
- Mr. Rajnish Sarna has resigned as Joint Managing Director and will continue his association with the company as a Non-Executive, Non-Independent Director.
- Ms. Lisa J. Brown has been designated as the Lead Independent Director.
- Dr. Marco Busch has been designated as a Senior Management Personnel.
Operational Updates
PI Industries noted that its QIP funds raised in 2020 have been fully utilized towards capital expenditure and investments in subsidiaries during the year. The company continues to monitor the impact of the New Labour Codes, with minor incremental liabilities recognized in the financial results. The consolidated performance highlights the company’s resilience, with both the Agro Chemicals and Pharma segments contributing to its global growth strategy.
Source: BSE
